EYVIVA
EYVIVA is a biopharmaceutical company developing first-in-class therapies to prevent retinal cell death in degenerative eye diseases like Age-Related Macular Degeneration and glaucoma. Its lead program is a highly potent anti-Fas Ligand monoclonal antibody that blocks apoptosis, a central upstream driver of retinal cell death and inflammation. The therapy is currently in late preclinical development with IND-enabling studies underway, targeting a unifying apoptotic pathway implicated across multiple retinal conditions.
- Biotechnology
- Drug Discovery & Therapeutics
- Healthcare Technology
Funding
Founders
Product
Problem
Age-Related Macular Degeneration and glaucoma cause progressive, irreversible vision loss through retinal cell death, and current treatments primarily manage late-stage consequences rather than preventing the underlying degeneration. Existing therapies do not intervene early enough in the disease process to preserve vision, leaving patients with limited options to halt disease progression.
Solution
EYVIVA is developing a first-in-class anti-Fas Ligand monoclonal antibody designed to block apoptosis, a central upstream driver of retinal cell death and inflammation. By targeting this unifying apoptotic pathway implicated in multiple retinal diseases, the therapy aims to preserve vision and slow disease progression across conditions like Age-Related Macular Degeneration and glaucoma. The program is currently in late preclinical development with IND-enabling studies underway, establishing safety, target engagement, and biomarkers of neuroprotection. The company's long-term vision is to shift treatment from managing late-stage consequences to preventing retinal cell death at its source, potentially building a platform therapy applicable across multiple sight-loss conditions.
Target Audience
Primary customers are patients with degenerative retinal diseases such as Age-Related Macular Degeneration and glaucoma, as well as ophthalmology clinics and research institutions seeking disease-modifying therapies that prevent vision loss.
Features
- Highly potent anti-Fas Ligand monoclonal antibody specifically designed to block apoptosis in retinal cells
- Targets a unifying upstream apoptotic pathway implicated in multiple retinal diseases, offering broad therapeutic applicability
- Currently in late preclinical development with IND-enabling studies underway, establishing a clear path toward clinical translation
- Focus on establishing safety, target engagement, and biomarkers of early neuroprotection signals in at-risk patients
- Platform therapy potential to protect vision across multiple degenerative eye conditions beyond AMD and glaucoma